Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06343948
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-03-27
Brief Title:
A Study Comparing BL-B01D1 With Chemotherapy of Physicians Choice in Patients With Unresectable Locally Advanced Recurrent or Metastatic HRHER2- Breast Cancer
Sponsor:
Sichuan Baili Pharmaceutical Co Ltd
Organization:
Sichuan Baili Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physicians Choice in Patients With Unresectable Locally Advanced Recurrent or Metastatic HRHER2- Breast Cancer After Failure of at Least One Prior Line of Chemotherapy
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a registered phase III randomized open-label multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced recurrent or metastatic HRHER2- breast cancer after failure of at least one prior line of chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None